Murine D17Wsu104e (SF20) is a bone marrow stroma-derived growth factor, sometimes called IL25 (not to be confused with IL17E/IL25). SF20 is expressed in bone marrow, spleen stroma cells, resting mononuclear cells, resting CD8+ and CD19+ cells and activated CD8+ T-cells. SF20 has also been shown to bind to the surface of cells expressing the receptor TSA-1 (Thymic shared Ag-1). Among its biological activities, SF20 stimulates the proliferation of FDCP2 cells (a mouse factor-dependent hemopoietic cell line) and mouse lymphoid cells.

Interferon lambda 1, also known as interleukin 29, belongs to the newly classified type III interferon family. Expression of IFNL1 is seen in a variety of cell types in response to viral infection or treatment with double-stranded RNA. IFNL1 exerts antiviral activity and upregulation of MHC class I antigen expression. It signals through a heterodimeric receptor complex composed of IL10RB and IFNLR1 which activates the JAK-STAT pathway, phosphorylating STAT1, STAT2, and STAT3.

Interferon lambda 2, also known as interleukin 28A, belongs to the newly classified type III interferon family. Expression of IFNL2 is seen in a variety of cell types in response to viral infection or treatment with double-stranded RNA. IFNL2 exerts antiviral activity by activating mx proteins, 2',5'-oligoadenylate synthetase, and interferon regulatory factor 9. It signals through a heterodimeric receptor complex composed of IL10RB and IFNLR1 which activates the JAK-STAT pathway, phosphorylating STAT1, STAT2, and STAT3.

Interferon lambda 3, also known as interleukin 28B, belongs to the newly classified type III interferon family. Expression of IFNL3 is seen in a variety of cell types in response to viral infection or treatment with double-stranded RNA. IFNL3 exerts antiviral activity and up regulation of MHC class I antigen expression. It also plays a role in Toll-like receptor (TLR)-induced antiviral defense. IFNL3 signals through a heterodimeric receptor complex composed of IL10RB and IFNLR1 which activates the JAK-STAT pathway, phosphorylating STAT1, STAT2, and STAT3. In individuals with chronic hepatitis C, the presence of specific polymorphisms near this gene has been associated with an increased response in treatment for the condition with interferon and ribavirin.

Interleukin-10 (IL10), also known as cytokine synthesis inhibitory factor (CSIF), is the charter member of the IL10 family of F-helical cytokines that also includes IL19, IL20, IL22, IL24, and IL26/AK155. While the gene which encodes IL10 is comprised of 178 amino acids, the active protein only contains 160 amino acids. IL10 contains two intrachain disulfide bridges and is expressed as a 36 kDa noncovalently associated homodimer. The IL10 dimer binds to two IL10 RF/IL10R1 chains, resulting in the recruitment of two IL10 RH/IL10R2 chains and the activation of a signaling cascade involving JAK1, TYK2, and STAT3. IL10RH does not bind IL10 directly, but is required for signal transduction. IL10 is also a critical molecule in the control of viral infections, allergic reactions and autoimmune inflammation. IL10 promotes phagocytic uptake and Th2 responses, but suppresses antigen presentation and Th1 pro-inflammatory responses. IL10 is secreted by many activated hematopoietic cell types, as well as hepatic stellate cells, keratinocytes and placental cytotrophoblasts. Human IL10 is active on mouse cells; however mouse IL10 does not act on human cells.

Interleukin-10 (IL10) is an immunosuppressive cytokine produced by a variety of mammalian cell types including macrophages, monocytes, T-cells, B-cells and keratinocytes. IL10 inhibits the expression of pro-inflammatory cytokines such as IL1 and TNFα. Like IL4, IL10 enhances humoral immune responses and attenuates cell-mediated immune reactions. Human IL10 is active on murine cells, but murine IL10 is inactive on human cells.

Interleukin-11 (IL11) is encoded by the IL11 gene and is a member of IL6 superfamily, which is distinguished based on its use of the common co-receptor gp130. IL11 is a multifunctional cytokine that was first isolated from bone marrow-derived stromal cells. IL11 receptor activation requires the formation of a complex that contains two IL11 molecules, two molecules of the ligand-binding IL11 RF subunit, and two molecules of the expressed cell signaling G-subunit, gp130. The functions of IL11 are that it directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells, and induces megakaryocyte maturation that results in increased platelet production.

Interleukin-11 (IL11) is a pleiotropic cytokine that was originally detected in the conditioned medium of an IL1α-stimulated primate bone marrow stromal cell line (PU-34) as a mitogen for the IL6-responsive murine plasmacytoma cell line T11. IL11 contains no cysteine residues or potential glycosylation sites. IL11 has multiple effects on both hematopoietic and nonhematopoietic cells. Many of the biological effects described for IL11 overlap with those of IL6. In vitro, IL11 can synergize with IL3, IL4 and SCF to shorten the G0 period of early hematopoietic progenitors. IL11 also enhances the IL3-dependent megakaryocyte colony formation. IL11 has been found to stimulate the T-cell dependent development of specific immunoglobulin-secreting B-cells.

Human interleukin-13 (IL13) is expressed by the IL13 gene located on chromosome 5 and is secreted by many cell types, especially T-helper type 2 (Th2) cells. The high solution form of IL13 is reported to be a monomer with two internal disulfide bonds that contribute to a bundled four F-helix configuration. Targeted deletion of IL13 in mice resulted in impaired Th2 cell development and indicated an important role for IL13 in the expulsion of gastrointestinal parasites. IL13 exerts anti-inflammatory effects on monocytes and macrophages, and can also inhibit the expression of inflammatory cytokines such as IL1beta, TNF-alpha, IL6 and IL8. IL13 has also been shown to enhance B-cell proliferation, as well as induce isotype switching, which results in an increased production of IgE. Human, mouse and rat IL13 share a low percentage of homology, but have cross species activity.

Human Interleukin-13 (IL13) is expressed by the IL13 gene located on the chromosome 5. IL13 is a 112 amino acid protein containing a proposed 20 amino acid signal peptide making it 132 amino acids total, and shares approximately 30% amino acid sequence homology to human IL4. Additionally, the two cytokines exhibit overlapping biological activities. Human IL13 is produced by activated Th0, Th1-like Th2-like and CD8 T-cells. Similarly to IL4, IL13 has multiple effects on the differentiation of monocytes/macrophages, and can suppress their cytotoxic functions.

IL13 variant is a natural variant of the wild-type IL13 as it has a Q110 (glutamine) instead of an R110 (arginine), which is associated with increased risk for asthma development. At homozygosity, IL13V is associated with higher levels of total serum IgE in some allergic rhinitis patients.

Interleukin-13 (IL13) is an immunoregulatory cytokine produced primarily by activated Th2 cells, along with mast cells and NK cells. Targeted deletion of IL13 in mice resulted in impaired Th2 cell development and indicated that IL13 plays an important role in the expulsion of gastrointestinal parasites. IL13 exerts anti-inflammatory effects on monocytes and macrophages and inhibits the expression of inflammatory cytokines such as IL1β, TNF-α, IL6 and IL8. IL13 has also been shown to enhance B-cell proliferation and to induce isotype switching which results in an increased production of IgE. It has been suggested that the blocking of IL13 and its downstream effectors could play a role in the mechanism of asthma. Human and murine IL13 are cross-species reactive.

Interleukin 13 (IL13) is an immunoregulatory cytokine produced primarily by activated Th2-cells, mast cells and natural killer (NK) cells. Targeted deletion of IL13 in mice resulted in impaired Th2 cell development, and indicated an important role for IL13 in the expulsion of gastrointestinal parasites. IL13 exerts anti-inflammatory effects on monocytes and macrophages, and inhibits the expression of inflammatory cytokines such as IL1β, TNF-α, IL6 and IL8. IL13 has also been shown to enhance B-cell proliferation and induce isotype switching, which results in an increased production of IgE. Blocking IL13 activity inhibits the pathophysiology of asthma.